| 针对分子靶点的抗肿瘤药物研究进展 |
| |
| 引用本文： | 林莉萍,丁健.针对分子靶点的抗肿瘤药物研究进展[J].中国新药杂志,2006,15(3):167-174. |
| |
| 作者姓名： | 林莉萍 丁健 |
| |
| 作者单位： | 中国科学院上海药物研究所,新药研究国家重点实验室肿瘤药理组,上海,201203 |
| |
| 摘 要： | 随着肿瘤药理、分子药理学研究的飞速发展，针对分子靶点的抗肿瘤药物研发已成为当今抗肿瘤药物研究开发的重要方向。笔者综述了近年来DNA拓扑异构酶抑制剂、蛋白酪氨酸激酶抑制剂、肿瘤新生血管生成抑制剂、磷脂酰肌醇-3激酶／蛋白激酶B／哺乳动物雷帕霉素靶体（PI3K-AKT-mTOR）信号通路抑制剂、细胞周期依赖性蛋白激酶抑制剂的临床应用和临床研究进展。
|
| 关 键 词： | 拓扑异构酶 酪氨酸激酶 新生血管生成抑制剂 |
| 文章编号： | 1003-3734（2006）03-0167-08 |
| 收稿时间： | 2005-09-28 |
| 修稿时间： | 2005年9月28日 |
Current status of investigations for molecular-targeted anti-tumor drugs |
| |
| LIN Li-ping,DING Jian.Current status of investigations for molecular-targeted anti-tumor drugs[J].Chinese Journal of New Drugs,2006,15(3):167-174. |
| |
| Authors: | LIN Li-ping DING Jian |
| |
| Institution: | Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China |
| |
| Abstract: | Along with the rapidly increased knowledge of molecular pharmacology and tumor pharmacology, molecular-targeted therapies have become one of the most achievable fields in the development of pharmaceuticals against cancers. This paper reviewed recent progresses in the pharmacotherapeutics and clinical studies of the molecular-targeted anti-tumor drugs, including topoisomerase inhibitor, protein tyrosine kinase inhibitor, tumor angiogenesis inhibitor, PI3K-AKT-mTOR inhibitor and cyclin-dependent kinase inhibitors. |
| |
| Keywords: | topoisomerase protein tyrosine kinase angiogensis inhibitor |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
